Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Case Studies / Finding Ocular Surface Inflammation
Research & Innovations Research & Innovations Cornea Anterior Segment Glaucoma

Finding Ocular Surface Inflammation

InflammaDry<sup>®</sup> – the first commercially available, rapid result, in-office test that detects elevated levels of inflammatory marker MMP-9 – helps document ocular surface inflammation

Quidel 9/11/2020 0 min read

Share

Robert J. Noecker is an internationally known glaucoma expert who specializes in cataract and micro-invasive glaucoma surgery. He is Assistant Clinical Professor of Ophthalmology at the Yale University School of Medicine, Clinical Professor of Surgery at the Frank Netter School of Medicine of Quinnipiac University, and practices at Ophthalmic Consultants of Connecticut, USA.

Noecker presents this third case study in the InflammaDry® series.

Background

The patient is a 67-year-old woman with moderate primary open angle glaucoma and a history of numerous glaucoma treatments over the past few decades. She had undergone surgery with a Xen gel stent in the left eye approximately three months prior to the consultation, and was using difluprednate once a day. Her IOP was 12 mm Hg.

She presented with increased eye redness and complained of unstable vision while reading, as well as a foreign body sensation – all symptoms were worse in the right eye than the left.

Noecker-CS-fig1.png

Diagnosis

The patient had superior nasal step visual field loss in both eyes with corresponding optic nerve and RNFL thinning. On brimonidine, bimatoprost and dorzolamide, her right eye IOP was 18 mm Hg.

She had significant ocular surface disease in both eyes, with the right being significantly worse than the left. After her previous surgery, she had continued using glaucoma medications in the right eye while not using them in the left eye. This corresponded to a more inflamed tear film and confirmed the cause of the patient’s symptoms.

The pro-inflammatory effect of glaucoma medications on the ocular surface is well documented. Benzalkonium chloride (BAK) is the agent most commonly implicated, but the active ingredient, pH and other excipients, as well as duration and frequency of application, have been linked to increased inflammation in ocular surface tissues. The changes are reversible with the use of tropical anti-inflammatory agents, but the longer the inflammatory changes have been present, the longer they take to dissipate.

Intervention and treatment

MMP-9 testing helped to confirm that the glaucoma medications significantly contributed to this patient’s ocular surface problems; approximately six months before, she had tested highly positive for the presence of MMP-9 in both eyes.

Noecker-CS-fig2.png

Noecker-CS-fig3.png

After a review of both ocular surface and glaucoma status, the patient was scheduled for surgery in her right eye with the goal of controlling her IOP without the further use of glaucoma medications.

The role of MMP-9

A baseline evaluation for the presence of MMP-9 in our glaucoma patients is standard protocol – and can be performed using the InflammaDry® MMP-9 rapid point-0f-care diagnostic test (Quidel Corporation, San Diego, CA, USA). In my experience, most glaucoma patients suffer from ocular surface disease, which often bothers them more than the glaucoma.

MMP-9 testing in all patients helps to guide therapeutic decisions, and objectively documenting ocular surface inflammation helps with patient education on available therapy options.

Patient outcome

MMP-9 testing in this patient corroborated the clinical findings. By eliminating the glaucoma medications and using antiinflammatory therapy in the form of corticosteroids, the changes were reversed through surgical intervention.

The patient was operated on successfully and is doing well off glaucoma medications, with an improving ocular surface status.

www.quideleyehealth.com

Download the Case Study as a pdf

View all InflammaDry® cases studies

Related Content

Omics
Turning Tides

January 9, 2024

3 min read

A new study shows evidence for sustained human-to-human transmission of mpox since 2016

“Pop” Goes the Sensor
Omics
“Pop” Goes the Sensor

January 19, 2022

1 min read

A new device could help scientists identify signs of arrhythmia, heart attack, and cardiac fibrosis

Improving Risk Stratification
Omics
Improving Risk Stratification

February 3, 2022

1 min read

Two genes have been identified that may be linked to prostate cancer outcomes

The Ultimate Vision for Rare Disease
Omics
The Ultimate Vision for Rare Disease

February 28, 2022

1 min read

Genomics and computational Ophthalmology can take rare disease diagnostics to the next level

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: